Beta-Blocker Discontinuation Non-inferior to Continuation in Stable Patients After MI: SMART-DECISION Trial
Key Points • In the randomized SMART-DECISION trial conducted in Korea, discontinuation of long-term beta blocker therapy was non–inferior to continuation... Read more.
CORALreef Add-on Shows Oral Enlicitide Lowered LDL-C More Than Guideline Recommended Oral Non-Statin Comparators
Key Points • In the phase 3 CORALreef Add-on trial, oral enlicitide decanoate added to background statin therapy produced a significantly greater reduction in... Read more.
IVUS-guided PCI was not Associated with Lower Risk of Target-Vessel Failure vs Angiography-guided PCI alone in High-risk Patients: OPTIMAL trial
Key Points • In the randomized OPTIMAL trial, IVUS-guided PCI did not reduce the risk of the primary patient oriented composite endpoint compared with angiography-guided... Read more.
SirPAD Finds Sirolimus-Coated Balloon Angioplasty Reduced Major Adverse Limb Events in Infrainguinal PAD
Key Points • In the randomized SirPAD trial, sirolimus-coated balloon angioplasty was noninferior and superior to uncoated balloon angioplasty for the primary... Read more.
Less Invasive FFR Comparable to FFR: Results from FAST III trial
Key Points • In the FAST III trial, a vFFR guided revascularization strategy was noninferior to an FFR guided strategy for the 1-year composite of death, myocardial... Read more.
2-Year Follow up of TRI-FR Trial: TEER Reduced HF Events in Severe Isolated Tricuspid Regurgitation
Key Points • In the extended 2 year follow up of the randomized TRI-FR trial, transcatheter edge to edge repair plus optimal medical therapy reduced the composite... Read more.
Intensive LDL C Targeting to <55 mg/dL Reduced Cardiovascular Events in ASCVD: The Ez-PAVE Trial
Key Points • In the randomized EZ-PAVE trial, an LDL C target of <55 mg/dL significantly reduced the 3-year risk of major cardiovascular events compared with... Read more.
Tirzepatide Lowers MACE vs Dulaglutide in SURPASS-CVOT Patients With Heart Failure
Key Points In SURPASS-CVOT, tirzepatide was previously shown to be non-inferior to dulaglutide for 3-point major adverse cardiovascular events (MACE-3) in adults... Read more.
Health360x.ai Successfully Implemented Decentralized Clinical Trials in Underserved Populations
Key Points: Health360x.ai is an AI-powered digital health platform designed to scale access to decentralized clinical trials (DCTs) by addressing infrastructure... Read more.
Sodium Zirconium Cyclosilicate Enables MRA Optimization in HFrEF with Hyperkalemia: Insights from the REALIZE-K Trial
Key Points: REALIZE-K trial was a double-blind, placebo-controlled, randomized withdrawal study investigating SZC’s ability to maintain normokalemia (NK) and... Read more.